Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression. To enhance prognosis of this fatal cancer, we validated the preclinical efficacy of measles virus (MV)-NIS, the vaccine strain of the oncolytic MV (MV-Edm), modified to include the NIS gene. Western blotting analysis confirmed that a panel of eight anaplastic thyroid cancer (ATC)-derived cell lines do not express NIS protein, but do express CD46, the MV receptor. In vitro cell death assays and in vivo xenograft studies demonstrate the oncolytic efficacy of MV-NIS in BHT-101 and KTC-3, ATC-derived cell lines. Radioactive iodine uptake along with single-photon emission computed tomography (SPECT)-computed tomography imaging of KTC-3 xenografts after 99 Tc m administration confirmed NIS expression in vitro and in vivo, respectively, after virus treatment. Adjuvant administration of RAI, to MV-NIS-treated KTC-3 tumors showed a trend for increased tumor cell killing. As current treatment for ATC is only palliative, and MV-NIS is currently Food and Drug Administration approved for human clinical trials in myeloma, our data indicate that targeting ATC with MV-NIS could prove to be a novel therapeutic strategy for effective treatment of iodine-resistant ATC and will expedite its testing in clinical trials for this aggressive disease.
INTRODUCTION
Incidence of thyroid cancer is currently on the rise and the American Cancer Society estimates that about 48 000 thyroid cancer cases will be diagnosed in the United States with an estimated 1700 deaths in 2011. 1 Although rare, anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer, accounting for 2% of all cases and 20--40% of the annual thyroid cancer deaths in the United States. 2 ATC are poorly differentiated tumors that exhibit resistance to most treatment modalities, consequently, the 1-year survival rate after diagnosis is only 5--15%. 3, 4 As single modality therapy has been shown to have a limited effect on ATC, multimodality therapy has become the treatment of choice in recent years, 5 with the hope of leading to at least reduced tumor mass and palliative control of the cancer.
Although most studies on prevention and therapy of ATC have concentrated on the use of small molecules that can inhibit the growth of ATC cell lines in culture and in mouse tumor explant models, along with others, we have evaluated virotherapies as potential treatments for anaplastic thyroid cancer (Supplementary Table 1) . 6--19 The virotherapies have included the restoration of the sodium iodide symporter (NIS), suicide therapy or oncolytic viruses that are conditionally replicative only within tumor cells. 20 Oncolytic viruses in particular have been exploited because anaplastic thyroid carcinomas represent potentially suitable targets for such specific tumor targeting because of the fact that they develop through progressive accumulation of changes in several oncogenic pathways, including p53 and retinoblastoma. 21, 22 With the aim of identifying an effective and fast acting therapeutic option for ATC, we focused on the measles virus (MV) as a potential therapeutic. The vaccine strain of the MV (MVEdm) propagates in a broad range of human tumor cells, 23, 24 and has been modified to include the NIS gene (MV-NIS) in order to allow radioiodine imaging and to facilitate adjuvant radioiodine therapy. 25 The presence of NIS in this virus is of particular significance for the treatment of ATC, because unlike welldifferentiated papillary or follicular thyroid cancers, which express NIS and are responsive to radioactive iodide (RAI) therapy, ATC lose NIS expression and are therefore resistant to RAI therapy. 21, 22 Expression of NIS allows cells to actively transport iodide ions into the cell. Thus, patients with thyroid cancer are typically treated with 131 I to destroy the NIS-expressing thyroid cancer while leaving most normal tissues undamaged. 26 Consequently, including NIS in the viral construct will lead to its overexpression and will render radioiodine-resistant ATC tumors susceptible to radioiodine therapy. 25 Insertion of NIS into MV presents a dual advantage in that it facilitates pharmacokinetic evaluation of MV oncolytic activity as well as allows for radioiodine imaging studies in vivo along with the potential to use RAI as an adjuvant therapy.
Preclinical studies have demonstrated the efficacy of MV-NIS against human multiple myeloma, 24 ovarian 27 and hepatocellular carcinoma 28 in vivo. Also MV-NIS has already been approved by the Food and Drug Administration for human clinical trials. Thus, a demonstration of its effectiveness in ATC could facilitate implementation of a clinical trial. In the present report, we demonstrate for the first time that MV-NIS can be used as a novel therapeutic to suppress the growth of ATC-derived xenograft tumors in vivo. We also demonstrate that ectopic expression of NIS in these xenografts allows for noninvasive imaging followed by the subsequent use of radioactive iodine as an adjunct therapy, enhancing treatment options for radioiodine-resistant anaplastic thyroid cancer.
MATERIALS AND METHODS

Cell culture
The ATC-derived cell lines FRO, SW1736, BHT-101, KTC-2, KAT-4, KAT-18, OCUT-1 and KTC-3 (obtained from Dr John Copland, Mayo Clinic, Jacksonville, FL) were cultured in RPMI-1640 containing 10% fetal bovine serum, non-essential amino acids, sodium pyruvate, HEPES buffer and penicillin--streptomycin antimycotic. All cell lines were verified by DNA fingerprinting to be bona fide ATC cell lines according to Schweppe et al. 29 Vero (monkey kidney) cells were obtained from American Type Culture Collection (Manassas, VA, USA) and were cultured in Dulbecco's modification of Eagle medium, supplemented with 5% heat-inactivated fetal bovine serum. All cell lines were grown at 37 1C in a humidified atmosphere of 5% CO 2 .
MV-NIS virus production
A recombinant MV expressing the NIS gene was engineered at the Mayo Clinic and previously described. 24 The MV-NIS preparation used in all experiments in this study was produced by the Mayo Viral Vector Production Laboratory 27 and contains 3.5 Â 10 7 Vero cell tissue culture infective dose (TCID 50 ) per ml.
Western blot ATC cell lines were grown to 90% confluency in 100 cm plates. After 48 h cells were harvested in 50 ml M-PER (Pierce, Rockford, IL) vortexed, freezethawed three times and centrifuged at 15 000 g. Protein (50 ml aliquots) was used for immunoblotting, which was carried out using standard methods to determine expression levels of NIS and the MV receptor, CD46. NIS was detected with a mouse monoclonal antibody directed against amino-acid residues 468--643 of hNIS (dilution, 1:20 000) for 1.5 h at room temperature. 30 Anti-CD46 (Cell Signaling, Beverley, MA) was used per the manufacturer's specifications. Anti-human b-actin was used as a control to ensure uniform loading. Antibody binding was visualized by enhanced chemiluminescence (Pierce) and images were obtained using a KODAK IS4000MM digital imager (Rochester, NY, USA).
Cell viability assay ATC cell lines (BHT-101 and KTC-3) and Vero (control cells) were seeded in six-well plates (at 10 5 cells per well) and infected with MV-NIS at multiplicity of infection (MOI) 0, 0.02, 0.5 and 2 after 24 h. Cell survival was evaluated 6 days after infection using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability assay, 31 
Animal experiments
All animal experiments were approved by and performed in accordance with Mayo Institutional Animal Care and Use Committee guidelines. In all, 3-to 4-week-old female nude mice (Fox1 nu/nu ) were used in all experiments (Harlan Laboratories, Madison, WI). Mice were housed in a pathogen-free barrier facility with access to food and water ad libitum. To establish xenografts, mice were inoculated subcutaneously with 1 Â 10 7 BHT-101 or KTC-3 cells in 100 ml of RPMI (right flank for imaging and RAI therapy; both flanks for MV-NIS efficacy alone). Tumors were measured with calipers every 3 days, and volume was calculated using the formula; V tumor ¼ 0.5236 (l Â w Â h), where, l, w and h represent length, width and height. When tumors reached approximately 80--100 mm 3 , the mice were randomly divided into two groups of 10 each that received intratumoral (IT) injections of either phosphate-buffered saline (PBS) or 3.5 Â 10 6 TCID 50 of virus in a total volume of 100 ml, per tumor. Mice were observed daily and euthanized at the end of the study or if they met euthanization criteria (X15% loss of body weight, inability to access food and water, tumor ulceration, or tumor burden exceeding 1 cm 3 ).
Noninvasive imaging of xenografted tumors Oxygen (2 l/min) was used throughout induction of anesthesia and examination. Induction was performed with 4% isoflurane using an induction chamber (Summit Medical Equipment Company, Bend, OR). Mice were kept anesthetized throughout the full measurement by 2% isoflurane using a nose cone. Images were acquired using a Gamma Medica XSPECT system (Gamma Medica, Northridge, CA). The SPECT scan was performed with a low-energy, high-resolution parallel-hole collimator with a field view of 12.5 cm and reported resolution of 1 to 2 mm. A total of64 projections, 10 s per projection, were acquired with a total acquisition time of 13.46 min. The CT scan was performed with a circular orbit set at 256. Images were acquired at 80 kVp and 0.28 mA with a slice thickness of 50 mm and a reported resolution of 43 mm. Images were analyzed using the PMOD Biomedical Image Quantification and Kinetic Modeling Software (PMOD Technologies, Zurich, Switzerland). The level of 
I radiotherapy in vivo
A total of 20 mice with subcutaneous KTC-3 xenografts were used for this phase of the study. When tumors reached approximately 80--100 mm 3 in diameter, they were directly injected with 3.5 Â 10 6 TCID 50 /100 ml MV-NIS (n ¼ 17 mice) or 100 ml PBS (vehicle control, n ¼ 3 mice) using a 28-gauge needle. As our imaging studies demonstrated that maximum NIS expression was observed at day 3 after virus injection, 10 of the 17 mice were injected intraperitoneally with 2 mCi of 131 I, based on previous published studies, 33 72 h after MV-NIS injection and tumor growth monitored for 42 days.
Statistical analysis
The statistical significance of difference between control, and MV-NIStreated groups (with and without 125 I) for the in vitro experiments was determined by Student's two-tailed t-test and Po0.05 was considered significant. Tumor progression was assessed by repeated-measures analysis of variance utilizing SAS 9.2 software (SAS Institute, Cary, NC, USA).
RESULTS
NIS and CD46 expression in ATC cell lines
Resistance to radioactive iodine therapy is usually due to loss of NIS expression. 34 We evaluated a panel of eight ATC cell lines for NIS expression. Western blotting confirmed that all eight cell lines, 8/8 (100%) did not express NIS protein (Figure 1a ) and appeared to mimic the human cancer.
Efficacy of an oncolytic virus is dependent on the expression of the appropriate cellular receptors. Variations or lack of receptor expression could therefore impose limitations on the application of virus-mediated gene therapy. Two cell surface receptors, CD46 and signaling lymphocyte-activation molecule, have been identified as MV receptors. CD46 is ubiquitously expressed on all nucleated cells and acts as a receptor for the Edmonston strain and all vaccine strains derived from it. Signaling lymphocyteactivation molecule is selectively expressed on some T and B cells and is utilized by the Edmonston strain and wild-type strains that cannot use CD46 for cell entry. 35 Yamakawa et al. 36 have published the only study that has looked at CD46 expression in differentiated thyroid cancers, including follicular and papillary carcinomas, follicular adenomas, and normal thyroid. However, their study did not evaluate the expression of this receptor in dedifferentiated anaplastic thyroid cancer. As CD46 is the receptor used by the Edmonston strain of MV on nucleated cells, we evaluated all ATC cell lines by western blot analysis for expression of CD46. All cell lines tested (8/8, 100%) expressed varying levels of CD46 (Figure 1b) .
Anaplastic thyroid cancer-derived cell lines are susceptible to MV-NIS-mediated cell killing at high MOI Having determined that ATC-derived cells lines express CD46, the next step was to evaluate the efficacy of MV-NIS in these cells. We analyzed the sensitivity of two of the eight anaplastic thyroid cancer cell lines to MV-NIS at different MOI to determine the dose of virus required to obtain 50% or less killing of the cells. BHT-101 and KTC-3 were infected at MOIs of 0.02, 0.05 and 2 and evaluated for cell viability 24, 48 and 72 h later by crystal violet staining (Figure 2a ). Significant cytopathic effect by MV-NIS was observed in both ATC-derived cell lines only at a high MOI of 2 compared with the control Vero cells (Figures 2a and b) . Analysis of cell death was evaluated at 6 days post-virus infection. Infection of both BHT-101 and KTC-3 resulted in a 50% cell death at the maximum MOI of 2 in contrast to Vero control cells that were efficiently killed (90% cell death) at the lowest MOI of 0.02 (Po0.05). MOIs of 0.02 and 0.5 did not impact growth of both ATC cell lines (Figure 2b) . No cytopathic effect was observed when the same cells were mock-infected with growth media as a control.
MV-NIS suppresses growth of ATC xenografts demonstrating antitumor activity in vivo To determine the efficacy of MV-NIS in vivo, BHT-101 and KTC-3 xenografts were generated in athymic nude mice, two tumors per animal one on each flank. Animals were divided into two groups each for injection with either MV-NIS or PBS and evaluated for tumor growth depending on the treatment regimen (Figure 3 ). In the virus-treated group, each tumor was injected with a total 3.5 Â 10 6 TCID50 of MV-NIS. None of the mice in this study showed evidence of morbidity during tumor growth, and mice were euthanized when tumors reached a volume X1 cm 3 . Extensive tumor growth was observed in all groups treated with PBS ( Figure 4 ) and tumor growth reached 1 cm 3 by weeks 6--7. For the oncolytic efficacy of MV-NIS, virus was injected IT either as a single dose or a triple dose over a period of 3 consecutive days, in a total of 10 mice per experiment, which significantly suppressed tumor growth, in comparison with their PBS-treated controls, the effect being most dramatic in the KTC-3 xenografts (Figure 4) . BHT-101 tumors that were injected with a single dose of MV-NIS were suppressed by 1.5-to 2.3-fold, whereas those tumors that got a triple dose of MV-NIS were suppressed between 2-and 3-fold (Figures 4a and b) , compared with PBS-treated tumors. A single dose of MV-NIS seemed to be even more effective on KTC-3 xenografts, suppressing tumor growth by 4-to 5-fold (Figure 4c In vivo antitumor activity of MV-NIS is enhanced by adjuvant radioiodine treatment In addition to its oncolytic efficacy (Figure 4) , MV-NIS resulted in the restoration of NIS expression ( Figure 5 ), which allowed for adjuvant treatment of radioiodine. To determine whether a synergistic effect could be observed in ATC-derived tumors using a treatment regimen that included MV-NIS as well as radioiodine, we administered MV-NIS-treated KTC-3 xenografts with 2 mCi of 131 I per tumor and monitored tumor growth as a measure of time. Administration of radioactive iodine did appear to modestly impact tumor reduction (64.2% reduction in tumor volume) compared with MV-NIS alone (52.3% reduction in tumor volume) as assessed by measuring the areas under the respective curves ( Figure 6 ). However, this reduction was not significantly different between the two groups as measured by repeated-measures analysis of variance. Collectively these data confirm the efficacy of MV-NIS against ATC cell line xenografts in vivo and demonstrate its potential as a novel therapeutic for aggressive thyroid tumors that cannot concentrate iodide. Adjuvant 131 I therapy may require optimization to provide additional significant response above and beyond the oncolytic effect of MV-NIS by itself. gene as a potential therapeutic agent for this aggressive cancer. We evaluated ATC cell lines for expression of CD46, the receptor for MV Edmonston strain and demonstrated that receptor expression is not a limitation to the use of this agent as a therapeutic for ATC, because CD46 was expressed on all the cell lines analyzed (Figure 1b) . Our data also clearly indicate that MV-NIS treatment at an MOI of 2 does result in cell death in ATC cell lines in vitro (Figure 2 ), but more importantly we show that the virus can significantly suppress growth of ATC-derived xenografts in vivo (Figure 4 ). Further we demonstrate that treatment with MV-NIS results in ectopic expression of NIS ( Figure 5 ), both in vitro and in vivo, allowing for imaging (Figure 5b ) as well as the administration of radioiodine as an adjuvant therapy to hitherto radioiodine-resistant tumors. Specifically the combined treatment of MV-NIS and radioiodine resulted in a modestly enhanced impact on tumor growth ( Figure 6 ). The fact that ATCs are currently resistant to routinely used radioiodine treatment, are extremely aggressive, most often fatal, and MV-NIS is able to address these limitations strengthens the candidacy of this virus as a potential therapeutic agent for anaplastic thyroid cancer.
The in vitro studies demonstrate that although treatment of MV-NIS is able to induce cell death in ATC-derived cell lines only at the highest MOI tested, the expression of NIS is sufficient to allow for perchlorate sensitive radioactive iodine uptake within these cells to significant levels (Figures 2 and 4) . The lesser impact of MV-NIS on ATC-derived cells in vitro, could be due to multiple reasons including slower virus replication, lesser number of receptors on the cell surface of ATC cells or that the ATC cell lines are not as susceptible to MV as the control Vero cells. Studies demonstrating that MV-NIS has varied effect on cell death and radioactive iodine uptake in multiple cancer-derived cell lines including squamous cell carcinoma, 37 gliobastoma 38 and prostate cancer, 39 suggests that the efficacy of MV-NIS may be impacted by the cellular microenvironment. In this context, contrasting the relatively lower cell death and the significantly high uptake of 125 I in ATC-derived cell lines, suggests the possibility for the dual nature of this virus to be exploited for therapy of this aggressive cancer.
IT injection of MV-NIS in ATC-derived cell line xenografts led to significantly decreased tumor volume compared with control tumors (Figure 4 ) and resulted in NIS expression, allowing for noninvasive imaging as well as iodide uptake for adjuvant therapy. Our serial imaging studies clearly demonstrate that NIS expression is induced at day 2, peaks at day 3 and continues until day 22, the last day of measure, indicating the efficacy of MV-NIS for noninvasive imaging, a clear advantage to use of this virus. To obtain maximum benefit of adjuvant RAI treatment, the timing of maximal NIS expression is critical. Our data with the serial SPECT-CT imaging clearly demonstrates that NIS expression in KTC-3 xenografts peaks at day 3 after virus treatment and sustains as far out as 22 days after treatment (Figure 5b ). This shows the considerable temporal variation in NISmediated IT iodide uptake and the importance of reporter gene imaging to accurately determine the timing of additional radiotherapy, decide if additional radiotherapy would even be appropriate, and help evaluate an individual's specific response to therapy.
The addition of 131 I radiotherapy to MV-NIS-treated tumors resulted in a modest enhancement of MV-NIS oncolytic efficacy. Although we did see a trend toward decreased tumor volume, there was no significant benefit of combined 131 I with virotherapy over MV-NIS virotherapy alone. Possible explanations for this lack of synergy could be the inappropriate dosage of 131 I administration (2 mCi in this study). The glioblastoma 38 and prostate cancer study 39 both used 1 mCi of 131 I, whereas the pancreatic cancer study 40 used 3 mCi. Absence of synergy could also be the result of lack of a bystander effect from 131 I in certain tumor regions, particularly at the tumor periphery and in newly developing tumor nodules, which were not infected; and the possibility that KTC-3 cells are not sensitive to radiation at these dose levels. A similar lack of synergy has been observed with pancreatic cancer xenografts treated with MV-NIS. 40 In this case, the absence of synergy was due to a non-uniform IT distribution of MV-NIS infection, not lack of radio-sensitivity. 40 Also, relative resistance to ionizing radiation has been demonstrated in ATC-derived FRO cells. 41, 42 However, activation of JNK has been shown to enhance the radiosensitivity of ATC-derived cells, including FRO, C-643 and KTC-2 cells, 43 suggesting a possible combinatorial treatment strategy to enhance 131 I therapeutic efficacy. In addition, Li et al. 37 observed that cyclophosphamide enhances MV-NIS replication and thereby augments the efficacy of 131 I treatment in squamous cell carcinoma. Further studies need to be done to address these possibilities in order to have a benefit of combination therapy with MV-NIS and 131 I. In conclusion, we have demonstrated in preclinical studies that MV-NIS has the potential to function as a therapeutic agent in anaplastic thyroid cancer. ATC are poorly differentiated tumors that exhibit resistance to most treatment modalities, including routinely used radioactive iodine. As current treatment for ATC is only palliative, targeting it with MV-NIS that is oncolytic as well as allows for imaging and induces susceptibility to RAI therapy could prove to be a novel therapeutic strategy for effective treatment of anaplastic thyroid cancer thereby positively impacting clinical outcome of this aggressive cancer. Further, as MV-NIS is currently Food and Drug Administration approved for human clinical trials in multiple myeloma, our data will expedite its testing in clinical trials for this aggressive disease.
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